ES2123177T3 - Preparacion de absorcion percutanea que contiene buprenorfina. - Google Patents

Preparacion de absorcion percutanea que contiene buprenorfina.

Info

Publication number
ES2123177T3
ES2123177T3 ES95106861T ES95106861T ES2123177T3 ES 2123177 T3 ES2123177 T3 ES 2123177T3 ES 95106861 T ES95106861 T ES 95106861T ES 95106861 T ES95106861 T ES 95106861T ES 2123177 T3 ES2123177 T3 ES 2123177T3
Authority
ES
Spain
Prior art keywords
buprenorphine
percutaneous absorption
penetration enhancer
absorption preparation
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95106861T
Other languages
English (en)
Inventor
Shoichi Tokuda
Kazuhisa Ninomiya
Yasuhiro Fukushima
Shigeyuki Watanabe
Mitsuru Ochiai
Mutsuo Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nitto Denko Corp
Original Assignee
Nikken Chemicals Co Ltd
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Chemicals Co Ltd, Nitto Denko Corp filed Critical Nikken Chemicals Co Ltd
Application granted granted Critical
Publication of ES2123177T3 publication Critical patent/ES2123177T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE HA OBTENIDO UNA PREPARACION DE ABSORCION PERCUTANEA QUE ES EXCELENTE PARA LA PENETRACION EN LA PIEL DE UNA BUPRENORFINA ANALGESICA NO-NARCOTICA Y PUEDE MANTENER UN NIVEL DE SANGRE ALTO EN UN ESTADO ESTABLE POR ENCIMA DE UN LARGO PERIODO DE TIEMPO. LA PREPARACION DE ABSORCION PERCUTANEA PARA ADMINISTRAR HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA, CONTIENE UN SOPORTE QUE TIENE EN UNA SUPERFICIE DEL MISMO UNA CAPA DE ESCAYOLA QUE CONTIENE UN ADHESIVO SENSIBLE A LA PRESION, HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA, UN INTENSIFICADOR DE LA PENETRACION, EN DICHO INTENSIFICADOR DE LA PENETRACION SE CONTIENE UNA COMBINACION DE DE UN MONOGLICERIDO DE UN ACIDO GRASO QUE TIENE DE 6 A 8 ATOMOS DE CARBONO Y MIRISTATO DE ISOPROPILO, Y LA CAPA DE ESCAYOLA CONTIENE AL MENOS EL 10 DE SU PESO DE UN MONOGLICERIDO O ACIDO GRASO QUE TIENE DE 6 A 8 ATOMOS DE CARBONO Y AL MENOS 5 DEL PESO DE MIRISTATO DE ISOPROPILO, CON LA CONDICION DE QUE EL CONTENIDO DE TODO EL INTENSIFICADOR DE PENETRACION OSCILE ENTRE EL 25 Y EL 50 DEL PESO. EL USO COMBINADO DEL MONOGLICERIDO DE ACIDO GRASO Y EL MIRISTATO DE ISOPROPILO COMO INTENSIFICADOR DE LA PENETRACION SINERGETICAMENTE ELEVAN LA PENETRACION EN LA PIEL DEL HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA.
ES95106861T 1994-05-06 1995-05-05 Preparacion de absorcion percutanea que contiene buprenorfina. Expired - Lifetime ES2123177T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6094241A JP2819236B2 (ja) 1994-05-06 1994-05-06 経皮吸収製剤

Publications (1)

Publication Number Publication Date
ES2123177T3 true ES2123177T3 (es) 1999-01-01

Family

ID=14104817

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95106861T Expired - Lifetime ES2123177T3 (es) 1994-05-06 1995-05-05 Preparacion de absorcion percutanea que contiene buprenorfina.

Country Status (10)

Country Link
US (1) US5618555A (es)
EP (1) EP0680754B1 (es)
JP (1) JP2819236B2 (es)
KR (1) KR950031058A (es)
CN (1) CN1116525A (es)
AT (1) ATE171619T1 (es)
CA (1) CA2147918A1 (es)
DE (1) DE69505041T2 (es)
ES (1) ES2123177T3 (es)
TW (1) TW325406B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3576608B2 (ja) 1994-11-15 2004-10-13 日東電工株式会社 貼付剤および貼付製剤
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
ES2395268T3 (es) * 1997-09-04 2013-02-11 Demerx, Inc. Noribogaína para el tratamiento del dolor y la drogadicción
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
AU2001262683A1 (en) * 2000-06-02 2001-12-17 Teijin Limited Buprenorphine-containing patch
KR100448469B1 (ko) * 2001-10-26 2004-09-13 신풍제약주식회사 항염증제의 경피 조성물 및 장치
JP4668611B2 (ja) * 2002-05-31 2011-04-13 タイタン ファーマシューティカルズ インコーポレイテッド ブプレノルフィンの持続放出のための埋め込み型ポリマー製装置
KR20110120358A (ko) * 2002-06-10 2011-11-03 유로-셀티크 소시에떼 아노뉨 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
ES2359977T3 (es) * 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
HRP20070476T3 (en) 2003-07-25 2008-01-31 Euro-Celtique S.A. Treatment of dependence withdrawal
WO2006085521A1 (ja) * 2005-02-10 2006-08-17 Nihon University オピオイドレセプター拮抗剤を含有する経皮吸収用医薬組成物およびその製造方法、並びに前記拮抗剤の経皮吸収促進方法
EP1854456B1 (en) * 2005-02-28 2017-08-23 Hisamitsu Pharmaceutical Co., Inc. Pressure-sensitive adhesive base and medical adhesive patch including the pressure-sensitive adhesive base
KR20170029019A (ko) 2008-07-18 2017-03-14 바이오모드 컨셉츠 인코포레이티드 활성 성분을 방출하는 제품
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
EP2788003A4 (en) 2011-12-09 2015-05-27 Demerx Inc PHOSPHATESTER OF NORIBOGAIN
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
KR20250105683A (ko) 2016-10-31 2025-07-08 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
JP6695571B2 (ja) * 2016-12-05 2020-05-20 王子ホールディングス株式会社 経皮吸収型製剤
CN109487582A (zh) * 2018-11-19 2019-03-19 长沙浩然医疗科技有限公司 一种纯棉织物面料印染工艺
CN110013602B (zh) * 2019-04-17 2021-10-26 杨高云 用于治疗肢端型白癜风的手套及其制备方法
WO2022026362A1 (en) 2020-07-30 2022-02-03 Danimer Bioplastics, Inc. Biobased material for consumer goods packaging
US11584110B2 (en) 2020-07-30 2023-02-21 Pepsico, Inc. Multi-layered packaging films

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CH672888A5 (es) * 1986-11-07 1990-01-15 Mepha Ag
ATE109357T1 (de) * 1988-02-26 1994-08-15 Riker Laboratories Inc Transdermales estradiol als therapeutisches sytem.
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
DE69003632T2 (de) * 1989-02-28 1994-02-17 Teijin Ltd Pflaster sowie dessen herstellung.
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
ATE148633T1 (de) * 1990-03-28 1997-02-15 Noven Pharma Verfahren und vorrichtung zur freisetzung von arzneimittel an die haut
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions

Also Published As

Publication number Publication date
CN1116525A (zh) 1996-02-14
CA2147918A1 (en) 1995-11-07
KR950031058A (ko) 1995-12-18
DE69505041T2 (de) 1999-02-18
US5618555A (en) 1997-04-08
DE69505041D1 (de) 1998-11-05
TW325406B (en) 1998-01-21
EP0680754A2 (en) 1995-11-08
EP0680754A3 (en) 1996-03-06
ATE171619T1 (de) 1998-10-15
JPH07304672A (ja) 1995-11-21
EP0680754B1 (en) 1998-09-30
JP2819236B2 (ja) 1998-10-30

Similar Documents

Publication Publication Date Title
ES2123177T3 (es) Preparacion de absorcion percutanea que contiene buprenorfina.
BR9708632A (pt) Composto calcilìticos
AU7396294A (en) Incorporating poly-n-vinyl amide in a transdermal system
BR9403783A (pt) Uso de uma composição cosmética
HU9802889D0 (en) Percutaneous absorption type preparation
MX9206577A (es) COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
ITMI910584A1 (it) Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico.
MX9205389A (es) Composicion farmaceutica que contiene felbinac.
TW283645B (es)
DE69420419D1 (de) Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
ES2057064T3 (es) Preparado farmaceutico para administracion percutanea, que contiene bunazosina o sus sales.
ATE203158T1 (de) Perkutane zubereitung enthaltend tulobuterol
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
MY118301A (en) Local anesthetic for external use
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
DK0565519T3 (da) Illudinanaloge som antitumormidler
JPS6468316A (en) External plaster containing salbutamol
KR970014571A (ko) 1,2-디브로모-2,4-디시아노부탄과 파라하이드록시벤조산 에스테르와의 상승작용성 항미생물성 조성물
CA2170485A1 (en) Compositions Containing an Amino Acid Salt of Propionic Acid Non-Steroidal Anti-Inflammatory Agents and Caffeine
JPS5791913A (en) Pharmaceutical preparation of drug
AU610473B2 (en) 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
KR100387397B1 (es)
DK1062954T3 (da) Anvendelse af itakonsyre til regulering af det glykotiske stofskifte

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 680754

Country of ref document: ES